Exercise therapy in type 2 diabetes: state of the art

Slides:



Advertisements
Similar presentations
Secretory Phospholipase A2: A New Risk Factor and Soon a New Target of Therapy Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Division of.
Advertisements

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.
Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.
TREAT TO TARGET IN DIABETES: An Alternative pathway
Management of Stable Angina SIGN 96
0CTOBER 2010 An Approach for Sub-Saharan Africa. Dr. Linda Hawker, MD, CCFP General Practice Kelowna BC Canada.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36.
DR. ZAHOOR 1.  A 50 year old man presents to clinic with a complaint of central chest discomfort of 2 weeks’ duration, occurring after walking for more.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
ACC/AHA 2006 guidelines on the management of PAD.
Lesotho STEPS Survey 2012 Fact Sheet John Nkonyana Director Disease Control.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
Case I A 47 old male presents to your office for a yearly checkup. He smokes 40 cigarette/day, and examination detect wheezy chest and bronchospasm. His.
Synergic effect of exercise and nutrition intervention on disease model Wook Song, Ph.D. Health & Exercise Science Laboratory Institute of Sport Science.
ASSOCIATED CONDITIONS WITH DIABETES MELLITUS TYPE II.
Laboratory Testing For Cardiovascular Risk
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.
The EACPR EXPERT flowchart programme : a tool to prescribe exercise training in the setting of cardiac rehabilitation Dominique Hansen, PhD, FESC Hasselt.
The OPTImal CArdiac REhabilitation (OPTICARE) trial:
The EAPC Exercise Prescription in Everyday Practice & Rehabilitation Training (EXPERT) tool – a digital decision support system for optimize exercise prescription.
Dominique Hansen, PhD, FESC
CAD Exercise Adaptations
ALICE-PROTECT Study Yields Online Risk Prediction Tool in Diabetic Nephropathy From ESH 2016 | LB 1: Jean-Pierre Fauvel, MD CHU Lyon, Hôpital E Herriot,
The EXPERT tool: focus on prevention
Redefining Quality Care in T2DM Patients with CV Disease
Prevention of CVD in Diabetes
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Baseline characteristics and effectiveness results
Volume 1: Chronic Kidney Disease
CASE HISTORY ISCHEMIC HEART DISEASE
The Anglo Scandinavian Cardiac Outcomes Trial
ELIGIBILITY: MRC/BHF Heart Protection Study
Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.
Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’
Individualized physical training in CV prevention and rehabilitation
Dominique Hansen, PhD, FESC
Western Norway B-vitamin Intervention Trial
Exercise prescription in cardiovascular disease: guidelines vs
Chapter 4: Cardiovascular Disease in Patients with CKD
Prevalence of statin and beta-blocker use by clinical presentation
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
No conflict of interest
Optimizing exercise prescription: EXPERT tool
Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome  Jonas Faxén, Hong Xu,
Dominique Hansen, PhD, FESC Hasselt University
Anatomy and physiology of t2d
Prevention of CVD in Diabetes
Goals & Guidelines A summary of international guidelines for CHD
Train-the-Trainer Cases
Heart Disease Dr Stasinos Theodorou
Obesity Eppie Habashi.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Train-the-Trainer Cases
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
Train-the-Trainer Cases
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
MRRs and EMRRs for women with ACS
Putting Your Skills to the Test
Hazard ratios, with 95% confidence intervals as floating absolute risks, as estimate of association between category of updated mean haemoglobin A1c concentration.
Cardiovascular Epidemiology and Epidemiological Modelling
The benefits: exercise and cardiometabolic disease
Presentation transcript:

Exercise therapy in type 2 diabetes: state of the art Dominique Hansen, PhD, FESC

State-of-the-art exercise in T2DM Effectiveness of exercise intervention Prevention Treatment Novel/new exercise modalities Experimental manupulations Future of exercise therapy Where do we go from here?

Prevention of T2DM

Prevention of T2DM

Treatment of T2DM Qiu S, et al. PLoS One. 2014 Oct 17;9(10):e109767

Treatment of T2DM Umpierre D, et al. JAMA 2011; 305: 1790-99

Treatment of T2DM

Treatment of T2DM Umpierre D, et al. Diabetologia 2013; 56: 242-51

Optimizing exercises

Optimizing exercises

New/other exercise types

New/other exercise types

New/other exercise types

New/other exercise types

New/other exercise types Changes in peripheral insulin sensitivity after three months of endurance type exercise training with exercise sessions performed in either a fasted (solid lines) or postprandial state (dotted lines).

New/other exercise types   Fasted Postprandial Time effect Group *time effect Pretest Posttest P value Fasting blood glucose (mmol/l) 11.4 ± 4.4 9.8 ± 5.0 9.0 ± 2.9 7.8 ± 2.0 <0.05 NS HbA1c (%) 7.9 ± 1.8 7.7 ± 1.7 6.9 ± 0.9 6.7 ± 0.9 HbA1c (mmol/l) 63 ± 7 61 ± 7 52 ± 4 50 ± 4 M (mg/kg/min) 11.6 ± 12.9 20.6 ± 17.9 14.5 ± 15.7 25.1 ± 18.6 <0.01

New/other exercise types

New/other exercise types

New/other exercise types

New/other exercise types

New/other exercise types

New/other exercise types

Difficulties ahead Type 2 diabetes

Difficulties ahead AMI with PCI or CABG Hypercholesterolemia Heart failure Hypertension Sarcopenia Cardiomyopathy Type 2 diabetes Obesity Pacemaker/ICD Claudicating intermittens

And what to do with prescription of certain medications? Difficulties ahead And what to do with prescription of certain medications? Beta-blockers Statins Sulfonylurea/meglitinide Exogenous insulin administration … And what to do with certain adverse events during exercise testing? Myocardial ischemia Exercise-induced cardiac arrhythmias

And what to do with prescription of certain medications? Difficulties ahead And what to do with prescription of certain medications? Beta-blockers Statins Sulfonylurea/meglitinide Exogenous insulin administration … And what about safety precautions during exercise for all these indications? Nobody really knows….

Comparing different clinicians

Comparing different clinicians Case 1 Case 2 Case 3 Case 4 Case 5 Age: 65 years Body height: 171 cm Body weight: 65 kg Sex: male VO2max: 2500 ml/min (116% of predicted normal value) Resting HR: 55 bts/min Peak exercise HR: 123 bts/min Total cholesterol: 180 mg/dl Fasting glycaemia: 92 mg/dl Blood pressure: 145/82 mmHg Medication intake: beta-blocker, nitrate, statin, antiplatelet. Referred to rehabilitation for: acute myocardial infarction with PCI. Co-morbidities: None.   Age: 55 years Body height: 160 cm Body weight: 85 kg Sex: female VO2max: 1600 ml/min (108% of predicted normal value) Resting HR: 102 bts/min Peak exercise HR: 151 bts/min Total cholesterol: 267 mg/dl Fasting glycaemia: 108 mg/dl Blood pressure: 115/72 mmHg Medication intake: statin, ACE-inhibitor, orlistat, antiplatelet, metformin, sulfonylurea. Referred to rehabilitation for: obesity. Co-morbidities: type 2 diabetes. Additional information: gonarthrosis present. Age: 70 years Body height: 182 cm Body weight: 80 kg VO2max: 1500 ml/min (73% of predicted normal value) Resting HR: 52 bts/min Peak exercise HR: 112 bts/min Total cholesterol: 189 mg/dl Fasting glycaemia: 102 mg/dl Blood pressure: 125/80 mmHg Medication intake: statin, antiplatelet, beta-blocker, digitalis, mucolytics, bronchodilators. Referred to rehabilitation for: AMI with CABG. Co-morbidities: Heart failure with preserved ejection fraction, mild COPD. Body height: 165 cm Body weight: 90 kg VO2max: 1450 ml/min (90% of predicted normal value) Resting HR: 52 bts/min Peak exercise HR: 100 bts/min Total cholesterol: 234 mg/dl Fasting glycaemia: 115 mg/dl Blood pressure: 135/75 mmHg Medication intake: beta-blocker, statin, exogenous insulin, nitrate, erythropoietin. Referred to rehabilitation for: stable myocardial ischemia (threshold at 87 bts/min) Co-morbidities: renal failure, type 1 diabetes. Additional information: chronic aspecific low back pain present. Age: 79 years Body height: 170 cm Body weight: 59 kg VO2max: 1250 ml/min (88% of predicted normal value) Resting HR: 56 bts/min Peak exercise HR: 111 bts/min Total cholesterol: 178 mg/dl Fasting glycaemia: 125 mg/dl Blood pressure: 135/87 mmHg Medication intake: beta-blocker, bronchodilator, antiplatelet. Referred to rehabilitation for: peripheral vascular disease. Co-morbidities: cachexia and frailty, COPD.

Comparing different clinicians

Comparing different clinicians

Comparing different clinicians

Need for standardization

EXPERT tool

EXPERT tool

EXPERT tool

EXPERT tool

EXPERT tool

EXPERT Tool Digital, interactive decision support tool for exercise prescription Endorsed by the European Association of Preventive Cardiology www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/EXPERT-Tool

Time for telemedicine?

Drug-exercise interaction? + = Enhanced effects of exercise? + = Enhanced effects of drugs?

One last thing to (re)consider… But how, by what mechanism? By HbA1c reduction only?

Or maybe two things to (re)consider? This is often what we aim for…. But this is what we should aim for….

Dominique.hansen@uhasselt.be